BioVendor Group Unveils Latest Innovations in Immunodiagnostics and Molecular Diagnostics
|
By LabMedica International staff writers Posted on 08 Feb 2024 |
BioVendor Group (Brno, Czech Republic) is participating in Medlab Middle East 2024 where it is unveiling the latest innovations in immunodiagnostics and molecular diagnostics. Visitors to the BioVendor booth at the show can explore its portfolio and meet experts from BioVendor LM, BioVendor MDx, TestLine, DiaSource, and ViennaLab to discuss how its advancements can benefit their work in the field of laboratory medicine.
BioVendor Group CLIA solution brings a fully automated walk-away platform, which significantly increases the efficiency of the laboratory workflow. It redefines the standards of fluency of diagnostic laboratories and provides reliable results. The KleeYa analyzer is also part of the booth and is being demonstrated to visitors by an application specialist. The KleeYa analyzer is an open platform system that handles tests from various providers and can combine a wide variety of assay designs. KleeYa provides a unique approach to the use of different bead-based chemiluminescence technologies, offering superior assay performance and providing ease of use with cost containment.
At the BioVendor booth, TestLine is presenting its latest innovations in laboratory diagnostics that are shaping the future of diagnostics. Visitors can explore the versatility of its Microblot-Array technology and its impact on the development of laboratory diagnostics worldwide. Microblot–Array is a new generation of unique, immunoblot arrays in a microtiter plate format. It is designed for efficient multiplex diagnostics, enabling the simultaneous detection of multiple markers which can save time and lower costs. The technology eliminates the limited capacity of traditional BLOT strips and opens the opportunity for high throughput testing. Processing can be performed automatically using open ELISA analyzers. The evaluation is performed by the Microblot–Array Reader and software (SW). Results can be exported in various formats and the system can be connected to LIS.
DiaSource ImmunoAssays is also sharing the same booth as BioVendor Group where it is presenting its latest diagnostic devices, recent innovations, and equipment in the fields of immunodiagnostics and molecular diagnostics. On display are the company’s RIA instruments, IMMUNOBLOT instruments, ELISA instruments, and CLIA instruments. Experts from BioVendor MDx are presenting its expanded fastGEN portfolio with user-friendly kits for the analysis of various genes. The latest addition is the fastGEN TP53 Cancer kit which is intended for the detection of mutations in exons 2-11 as well as in the two non-canonical exons between exons 9 and 10. Visitors to the booth can also learn more about the all-in-one solution fastGEN including bioinformatic analysis software GENOVESA.
Latest Medlab 2024 News
- Anbio Biotechnology Presents Point-Of-Care IVD Solutions
- 77 Elektronika Showcases Latest Developments in Urinalysis
- Sansure Presents Future of Pathogen Identification and Disease Diagnosis
- Spinreact Presents Latest Developments in IVD
- Alifax Demonstrates Automated Solutions to Improve Performance in Laboratory Settings
- YHLO Unveils New iBC 900 Automated Chemistry Analyzer
- Lifotronic Demonstrates Latest Medical Innovations in Disease Diagnostics
- Dymind Introduces New High-End Hematology Analyzer with Innovative Functions
- DIRUI Exhibits Latest Lab Automation Technologies and Devices
- Beckman Coulter Unveils DxC 500 AU Chemistry Analyzer
- Boule Presents Next Generation Hematology and Clinical Chemistry Systems
- bioMérieux Showcases Advanced Generation of VIDAS Immunoassay Solution
- BioPerfectus Highlights Diagnostic Solutions for HPV & Cervical Cancer Screening, STIs and Vector-Borne Diseases
- Mindray Showcases Range of Advanced Total IVD Solutions
- Medlab Middle East 2024 Provides a Peek into the Laboratory of the Future
Channels
Clinical Chemistry
view channel
Blood Protein Signatures May Predict Brain Vessel Damage and Cognitive Decline
Cerebrovascular disease damages blood vessels in the brain and can contribute to tissue injury, microbleeds, white matter damage, stroke, cognitive decline, and dementia. Identifying people at higher risk... Read more
Flow Cytometry Tests Receive FDA Clearance for B-Cell Lymphoma Diagnosis
B-cell non-Hodgkin lymphoma (NHL), including chronic lymphocytic leukemia (CLL), requires accurate identification to guide further evaluation, monitoring, and treatment. In 2026, an estimated 79,320 people in the U.... Read moreMolecular Diagnostics
view channel
DNA Methylation May Predict Treatment Response in Myelodysplastic Syndromes
Myelodysplastic syndromes (MDS) are disorders in which the bone marrow does not produce healthy blood cells normally. Treatment selection can be challenging because clinicians cannot reliably predict which... Read more
Circulating Tumor DNA Test Identifies Complete Immunotherapy Responders
Immune checkpoint inhibitors have transformed treatment for many metastatic cancers, with some patients achieving durable disease control. However, clinicians remain uncertain about how long therapy should... Read moreHematology
view channel
New Reference Ranges Clarify Normal Neutrophil Counts in Duffy-Null Patients
Duffy-null status is a common genetic trait associated with naturally lower circulating white blood cell counts. It affects about 10% of the U.S. population and more than 66% of people with African or... Read more
Newly Certified FISH Probes Support Cytogenetic Testing in Blood Cancers
Hematological malignancies such as non-Hodgkin lymphoma, acute lymphoblastic leukemia, chronic lymphoid leukemia, and multiple myeloma require assessment of key cytogenetic abnormalities.... Read more
Genetic Testing Offers Opportunities for Earlier Blood Disorder Carrier Identification
Inherited hemoglobin disorders can affect oxygen transport, yet individuals who carry only a trait may remain unaware of their status. People with sickle cell trait or beta-thalassemia trait often have... Read more
New Risk-Stratification Tool Predicts Relapse After Blinatumomab in Childhood ALL
Acute lymphoblastic leukemia in children and young people requires careful assessment of relapse risk, particularly as treatment approaches move beyond standard chemotherapy. Traditional relapse predictors... Read moreImmunology
view channel
Antibody Testing Informs Melioidosis Diagnosis and Surveillance in Emerging Regions
Melioidosis is a serious and sometimes fatal infection caused by the soil- and water-dwelling bacterium Burkholderia pseudomallei. People and animals can contract the disease through exposure to contaminated... Read more
Exhaled Breath Particles Reveal Virus-Specific Antibodies in the Lower Airways
Respiratory viruses such as influenza virus, SARS-CoV-2, and respiratory syncytial virus (RSV) require immune protection across the airway mucosa. Antibodies in the respiratory tract lining are important... Read moreMicrobiology
view channel
Gastrointestinal Flex Assay Gains EU Certification for Tailored Pathogen Testing
Gastrointestinal infections can be caused by bacterial, viral, or parasitic pathogens, making targeted test selection important for clinical laboratories. Fixed syndromic panels may be broader than necessary... Read more
Molecular Panels Gain FDA Clearance for One-Hour Gastrointestinal Pathogen Testing
Acute infectious gastroenteritis, caused by viral, bacterial, and parasitic pathogens, remains a significant global health concern that inflames the gastrointestinal tract. Symptoms such as diarrhea, vomiting,... Read morePathology
view channel
Review Highlights Progress and Validation Needs for AI in Digital Pathology
Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read more
Breakthrough-Designated Cytology Test Supports Oral Cancer Risk Assessment
Oral cavity and oropharyngeal cancers remain a significant diagnostic challenge, with more than 60,000 Americans expected to be diagnosed in 2026 and more than 13,000 expected to die from these cancers.... Read more
AI Pathology Approach Closely Aligns With Breast Cancer Genomic Risk Classification
In early-stage breast cancer, precision oncology relies on biological information to guide personalized treatment decisions. Because access to tissue-based genomic testing may be limited, there is growing... Read moreTechnology
view channel
New qPCR Master Mixes Offer Broad Compatibility for Routine Research
Quantitative PCR (qPCR) workflows require consistent reagent performance across instruments and assay formats. Laboratories must also manage costs without changing established protocols.... Read more
Multi-Agent AI Framework Supports Laboratory Quality and Workflow Monitoring
Clinical laboratories analyze blood, urine, tissue, and other bodily fluids to support disease diagnosis and treatment. Rising test volumes, workforce shortages, and increasingly complex diagnostics are... Read moreIndustry
view channel
Siemens Healthineers Begins Transition Toward Standalone Olyrian Diagnostics Business
Siemens Healthineers has begun carving out its in vitro diagnostics business, which will operate as Olyrian Diagnostics. The new name will be introduced in stages as the business prepares to become a standalone... Read more
Agilent Completes Acquisition of Digital Pathology Platform Developer Proscia
Agilent Technologies has completed its acquisition of Proscia, a provider of digital pathology software for clinical and life sciences applications. The transaction involved a cash payment of USD 240 million... Read more
New Diagnostics Company Onvaro Formed to Expand Decentralized Testing
Sapphiros, a diagnostics platform backed by investment funds managed by KKR, and binx health, a point-of-care diagnostics company backed by Hildred, have combined to form Onvaro. The new diagnostics company... Read more








